Li Chaofeng, Tang Tao, Wang Wenyue
Department of General Surgery, China-Japan Friendship Hospital, Beijing 100029, China.
Gastroenterol Res Pract. 2020 Apr 6;2020:3232950. doi: 10.1155/2020/3232950. eCollection 2020.
To investigate the efficacy and safety of the combination use of tegafur and apatinib as a first-line therapy strategy in advanced gastric cancer (GC).
The present study included a total of 62 advanced GC patients. The patients were randomized into the combined group (treated with both tegafur and apatinib) and the control group (treated with only tegafur). Treatment efficacy, KPS score, nutrition condition, and progression-free survival time (PFS) were recorded.
Both the response and disease control rates were significantly higher in the combined group. The PFS time was remarkably higher and the KPS score was significantly reduced in the combined group after treatment. After treatment, both groups showed significantly increased nutrition risk, but the rates of patients with nutrition risk or innutrition were remarkably higher in the combined group. The ADR rates were also significantly higher in the combined group.
The combination use could achieve good efficacy and prolong patients' PFS time; however, apatinib also reduced the patients' quality of life and enhanced the nutrition risk and adverse drug reactions.
探讨替加氟与阿帕替尼联合使用作为晚期胃癌（GC）一线治疗策略的疗效和安全性。
本研究共纳入62例晚期GC患者。将患者随机分为联合组（接受替加氟和阿帕替尼治疗）和对照组（仅接受替加氟治疗）。记录治疗疗效、KPS评分、营养状况和无进展生存期（PFS）。
联合组的缓解率和疾病控制率均显著更高。联合组治疗后的PFS时间显著更长，KPS评分显著降低。治疗后，两组的营养风险均显著增加，但联合组营养风险或营养不良患者的比例显著更高。联合组的不良反应发生率也显著更高。
联合使用可取得良好疗效并延长患者的PFS时间；然而，阿帕替尼也降低了患者的生活质量，增加了营养风险和药物不良反应。
